Merck, Addex Parkinson’s Venture To Develop Treatments That Target Glutamate Receptor
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.
You may also be interested in...
Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.
Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.
Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
Dosing and efficacy endpoint of the trial have been informed by earlier studies, including a failed Phase III.